<DOC>
	<DOCNO>NCT00403416</DOCNO>
	<brief_summary>This study evaluate efficacy safety AEB071 prevent acute rejection kidney transplantation , combine tacrolimus first 3 month myfortic thereafter .</brief_summary>
	<brief_title>Efficacy Safety AEB071 Plus Tacrolimus ( Converted Mycophenolic Acid After 3 Months ) , Renal Transplant Patients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Inclusion criterion Male female patient race 18 year old Adult recipient kidney transplant decease live donor Recipients function Kidney : . Graft must functional later 36h transplantation . Exclusion criterion Need medication prohibit protocol Patients donor infect hepatitis B C , HIV . Patients history cancer Patients severe systemic infection Patients heart diseases ( family history ) associate increase risk arrhythmia . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>AEB071</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Mycophenolic acid</keyword>
	<keyword>Basiliximab</keyword>
	<keyword>Rejection</keyword>
	<keyword>Kidney function</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>